To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Latest action: Referred to the House Committee on Energy and Commerce.

Voted 5/3/2022View source

Roll-call record

How representatives voted

0 yea·0 nay

No roll-call votes recorded for this bill yet.